The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity

Open Cardiovascular Medicine Journal

Volumn 6, Issue 1, 2012, Pages 147-155

  Paspala, Ioanna ^a   Katsiki, Niki ^a   Kapoukranidou, Dorothea ^a   Mikhailidis, Dimitri P ^b   Tsiligiroglou Fachantidou, Anna ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Appetite; Cardiovascular risk; Ghrelin; Insulin; Leptin; Neuroendocrine mechanisms; Obesity; Psychobiology

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN; LORCASERIN; PEPTIDE YY; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EATING HABIT; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; FOOD PREFERENCE; HIGH RISK PATIENT; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUNGER; HYPERPHAGIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MENTAL DISEASE; METABOLIC SYNDROME X; NONHUMAN; NUTRITIONAL STATUS; OBESITY; OVERNUTRITION; PHYSICAL INACTIVITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SATIETY; UNSPECIFIED SIDE EFFECT;

EID: 84880639507     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401206010147     Document Type: Review

References (139)

1. Smit HJ, Kemsley EK, Tapp HS, et al. Does prolonged chewing reduce food intake? Fletcherism revisited. Appetite 2011; 57: 295-8
2. Booth DA. Physiological regulation through learnt control of appe-tites by contingencies among signals from external and internal en-vironments. Appetite 2008; 51: 433-41.
3. Soboļeva U, Lauriņa L, Slaidiņa A. The masticatory system--an overview. Stomatologija 2005; 7: 77-80.
4. Bourne MC. Food Texture and Viscosity: Concept and Measure-ment. 2nd ed. Elsevier Science & Technology Book. USA: Aca-demic Press 2002
5. Booth DA. Learnt reduction in the size of a meal. Measurement of the sensory-gastric inhibition of eating from conditioned satiety. Appetite 2009; 52: 745-9
6. Zheng H, Patterson LM, Berthoud HR. Orexin signaling in the ventral tegmental area is required for high-fat. appetite induced by opioid stimulation of the nucleus accumbens. J Neurosci 2007; 27: 11075-82
7. Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol 2008; 59: 55-92
8. Booth DA. The basics of quantitative judgment. How to rate the strength of appetite for food and its sating. Appetite 2009; 53: 438-41
9. Mennella JA, Pepino MY, Reed DR. Genetic and environmental determinants of bitter perception and sweet preferences. Paediatrics 2005; 115: 216-22
10. Janssen P, Vanden Berghe V, Verschueren S, et al. Review Article: the role of gastric motility in the control of food intake. Aliment Pharmacol Ther 2011; 33: 880-94
11. Rogers PJ. Eating habits and appetite control: a psychobiological perspective. Proc Nutr Soc 1999; 58: 59-67
12. Dhillo WS. Appetite regulation: an overview. Thyroid 2007; 17: 433-45
13. Monro JA, Mishra S. Glycemic impact as a property of foods is accurately measured by an available carbohydrate method that mimics the glycemic response. J Nutr 2010; 140: 1328-34
14. Rolls BJ, Roe LS, Meengs JS. Reductions in portion size and en-ergy density of foods are additive and lead to sustained decreases in energy intake. Am J Clin Nutr 2006; 83:11-7
15. Renaldi O, Pramono B, Sinorita H, et al. Hypoadiponectinemia: A risk factor for metabolic syndrome. Acta Med Indones 2009; 41: 20-4
16. Rolls ET. Brain mechanisms underlying flavour and appetite. Phi-los Trans R Soc Lond B Biol Sci 2006; 361: 1123-36
17. Grabenhorst F, Rolls ET, Bilderbeck A. How cognition modulates affective responses to taste and flavor: top-down influences on the orbitofrontal and pregenual cingulate cortices. Cereb Cortex 2008; 18: 1549-55
18. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a re-evaluation. Diabetes 2011; 60: 2441-9
19. Chaput JP, Tremblay A. The glucostatic theory of appetite control and the risk of obesity and diabetes Glucose homeostasis and obe-sity. Int J Obes 2009; 33: 46-53
20. Campfield LA, Smith FJ. Blood glucose dynamics and control of meal initiation: a pattern detection and recognition theory. Physiol Rev 2003; 83: 25-58
21. Kendall CWC, Esfahani A, Sanders LM, et al. The effect of a pre-load meal containing resistant starch on spontaneous food intake and glucose and insulin responses. J Food Technol 2010; 8: 67-73
22. Joseph RJ, Alonso-Alonso M, Bond DS, et al. The neurocognitive connection between physical activity and eating behaviour. Obes Rev 2011; 12: 800-12
23. Sandoval DA, Ryan KK, Kloet AD, et al. Female rats are relatively more sensitive to reduced lipid versus reduced carbohydrate avail-ability. Nutr Diabetes 2012; 2: e27
24. Halton ThL, Hu FB. The effects of high protein diets on ther-mogenesis, satiety and weight loss: a critical review. J Am Coll Nutr 2004; 23: 373-85
25. Henry S. Koopmans. Hepatic control of food intake. Appetite 1984; 5: 127-31
26. Nicolaidis S. What determines food intake? the ischymetric theory. Physiology 1987; 2: 104-7
27. Nicolaidis S, Even P. Physiological determinant of hunger, satia-tion, and satiety. Am J Clin Nutr 1985; 42: 1083-92
28. Rogers K. The Digestive System. 1st ed. New York: Britannica Educational Publishing 2011.
29. National Digestive Diseases Information Clearinghouse. Your Digestive System and How It Works. NIH Publication No. 08-2681. 2008
30. Booth DA. Lines, dashed lines and "scale" ex-tricks. Objective measurements of appetite versus subjective tests of intake. Appetite 2009; 53: 434-7
31. Lutter M, Nestle EJ. Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr. 2009; 139: 629-32
32. Griffioen-Roose S, Mars M, Siebelink E, et al. Protein status elicits compensatory changes in food intake and food preferences. Am J Clin Nutr 2012; 95: 32-8
33. Veldhorst M, Smeets MA, Soenen S, et al. Protein-induced satiety: Effects and mechanismsof different proteins. Physiol Behav 2008; 94: 300-7
34. Hall WL, Millward DJ, Long SJ, et al. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr 2003; 89: 239-48
35. Havel PJ. Section IV: Lipid modulators of islet function. update on adipocytes hormones regulation of energy balance and carbohy-drate/lipid metabolism. Diabetes 2004; 53: S143-51
36. Luhovyy BL, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake and satiety. J Am Coll Nutr 2007; 26: 704S-12S
37. Murphy KG, Bloom SR. Gut hormones and the regulation of en-ergy homeostasis. Nature 2006; 444: 854-9
38. Pupovac J, Anderson GH. Dietary peptides induce satiety via cholecystokinin-a and peripheral opioids receptors in rats. J Nutr 2002; 3: 2775-80
39. Ritter RC. Gastrointestinal mechanisms of satiation for food. Physiol Behav 2004; 81: 249-73
40. Van der Horst K, Oenema A, Ferreira I, et al. A systematic review of environmental correlates of obesity-related dietary behaviours in youth. Health Educ Res 2006; 22: 203-26
41. Leigh GE. Emotional influences on food choice: Sensory, physio-logical and psychological pathways. Physiol Behav 2006; 1: 53-61
42. Ahima RS, Antwi DA. Brain regulation of appetite and satiety. J Endocrinol Metab Clin North Am. 2008; 37: 811-23
43. Christensen L. Functional food carbohydrates. Biliaderis CG, Izy-dorczyk MS. Ed. RC Press 2006; 435-69
44. EUFIC. Appetite-it's a brain thing. Neural ensemble coding of satiety states. Neuron 2006; 51: 483-94
45. Dallma MF. Stress-induced obesity and the emotional nervous system. Trends Endocrinol Metab 2009; 21: 159-65
46. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008; 18: 158-68
47. Williams KW, Scott MM, Elmquist JK. From observation to ex-perimentation: leptin action in the mediobasal hypothalamus. Am J Clin Nutr 2009; 89: 985S-90S
48. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of ab-dominal obesity are better discriminators of cardiovascular risk fac-tors than BMI: a meta-analysis. J Clin Epidemiol 2008; 61: 646-53.
49. De Koning L, Merchant AT, Pogue J, Anand SS. Waist circumfer-ence and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007; 28: 850-6.
50. Asia Pacific Cohort Studies Collaboration. Central obesity and risk of cardiovascular disease in the Asia Pacific Region. Asia Pac J Clin Nutr 2006; 15: 287-92.
51. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; In-ternational Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Asso-ciation; World Heart Federation; International Atherosclerosis So-ciety; and International Association for the Study of Obesity. Cir-culation 2009; 120: 1640-5.
52. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-21.
53. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366(9491): 1059-62.
54. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Asso-ciation; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Asso-ciation/National Heart, Lung, and Blood Institute Scientific State-ment. Circulation 2005; 112: 2735-52.
55. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classi-fication of diabetes mellitus provisional report of a WHO consulta-tion. Diabet Med 1998; 15: 539-53.
56. Bachar GN, Dicker D, Kornowski R, Atar E. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects. Am J Cardiol 2012; 110: 534-8.
57. Sacks HS, Fain JN. Human epicardial fat: what is new and what is missing? Clin Exp Pharmacol Physiol 2011; 38: 879-87.
58. Karayannis G, Giamouzis G, Tziolas N, et al. Association between epicardial fat thickness and weight homeostasis hormones in pa-tients with noncachectic heart failure. Angiology 2012 May 30.[Epub ahead of print]
59. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology-emerging clinical applica-tions. Nat Clin Pract Endocrinol Metab 2006; 2: 318-27
60. Sahu A. Leptin signalling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 2003; 24: 225-53
61. Koch A, Weiskirchen R, Zimmermann HW, et al. Relevance of serum leptin and leptin-receptor concentrations in critically Ill patients. Mediators Inflamm 2010; 2010. pii:473540
62. Hroussalas G, Kassi E, Dalamaga M, et al. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in over-weight/obese postmenopausal women. Maturitas 2008; 59: 339-49
63. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152: 93-100
64. Benoit SC, Clegg DJ, Seeley RJ, et al. Insulin and leptin as adipos-ity. Signals Recent Prog Horm Res 2004; 59: 267-85
65. Flakoll PJ, Jensen MD, Cherrington AD. Diabetes mellitus: a fun-damental and clinical text. 3rd ed. Philadelphia: Lippincott Wil-liams & Wilkins 2004.
66. Szanto I, Kahn CR. Selective interaction between leptin and insulin signalling pathways in a hepatic cell line. Proc Natl Acad Sci 2000; 97: 2355-60
67. Margetic S, Gazzola C, Pegg1 GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 6: 1407-33
68. Enriori PJ, Evans AE, Sinnayah P, et al. Leptin resistance and obesity. Obesity 2006; 14: 254-8
69. Belgardt BF, Brüning JC. CNS leptin and insulin action in the control of energy homeostasis. Ann NY Acad Sci 2010; 1212: 97-113
70. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26: 19-39
71. Malendowicz W, Rucinski M, Macchi C, et al. Leptin and leptin receptors in the prostate and seminal vesicles of the adult rat. Int J Mol Med 2006; 18: 615-8
72. Ukkola O, Poykko S. Ghrelin, growth and obesity. Ann Med 2002; 34: 102-108
73. Strat AL, Kokta ThA, Dodson MV, et al. Early signalling interac-tions between the insulin and leptin pathways in bovine myogenic cells. Biochim Biophys Acta 2005; 1744: 164-75
74. Selenscig D, Rossi A, Chicco A, et al. Increased leptin storage with altered leptin secretion from adipocytes of rats with sucrose-induced dyslipidemia and insulin resistance: effect of dietary fish oil. Metabolism 2010; 59: 787-95
75. Jequier E. Leptin signalling, adiposity, and energy balance. Ann NY Acad Sci 2002; 967: 379-88
76. Singh A, Wirtz M, Parker N, et al. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels. Proc Natl Acad Sci 2009; 106: 13100-5
77. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13: 803-11
78. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13
79. Truett GE, Parks EJ. Ghrelin: It's role in energy balance. J Nutr 2005; 135: 1313
80. Hameed S, Dhillo WS, Bloom SR. Gut hormones and appetite control. Oral Dis 2009; 15: 18-26
81. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60
82. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-30
83. Johnstone LE, Srisawat R, Kumarnsit E, et al. Hypothalamic ex-pression of NPY mRNA, vasopressin mRNA and CRF mRNA in response to food restriction and central administration of the orexi-genic peptide GHRP-6. Stress 2005; 8: 59-67
84. Kishimoto I, Tokudome T, Hosoda H, Miyazato M, Kangawa K. Ghrelin and cardiovascular diseases. J Cardiol 2012; 59: 8-13.
85. Sudar E, Dobutovic B, Soskic S, et al. Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. J Physiol Biochem 2011; 67: 195-204
86. Beaumont NJ, Skinner VO, Tan TM, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003; 278: 8877-80.
87. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-8
88. Makimura H, Feldpausch MN, Stanley TL, Sun N, Grinspoon SK. Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size. Clin Endocrinol (Oxf) 2012; 76: 220-7.
89. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the patho-physiology, atherogenicity and clinical significance of LDL sub-classes. Curr Vasc Pharmacol 2011; 9: 533-71.
90. Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipi-daemia. Curr Vasc Pharmacol 2010; 8: 820-30.
91. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007; 7: 53-72.
92. Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract 2012; 66: 843-53.
93. Rizzo M, Mikhailidis DP. Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardio-vascular risk. Clin Endocrinol (Oxf) 2012; 76: 177-8.
94. Germain N, Galusca B, Le Roux CW, et al. Constitutional thinness and lean anorexia nervosa display opposite concentrations of pep-tide YY, glucagon-like peptide 1, ghrelin and leptin. Am J Clin Nutr 2007; 85: 967-71
95. Budak E, Sánchez MF, Bellver J, et al. Interactions of the hor-mones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system. Fertil Steril 2006; 85: 1563-81
96. Stylianou Ch, Galli-Tsinopoulou A, Farmakiotis D, et al. Ghrelin and leptin levels in obese adolescents. Relationship with body fat and insulin resistance. Hormones 2007; 6: 295-303
97. Di{dotless}ez JJ, Iglesias P. The role of the novel adipocytes-derived hor-mone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300
98. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem 2009; 20: 831-9
99. Kraemer FB, Shen WJ. Hormone-sensitive lipase knockouts. Nutr Metabol 2006; 3:12
100. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterra-nean) population. Curr Med Res Opin 2010; 26: 713-9.
101. Chimonas T, Athyros VG, Ganotakis E, et al. Assessing the treat-ment effect in metabolic syndrome without perceptible diabetes (at-tempt) collaborative group. cardiovascular risk factors and esti-mated 10-year risk of fatal cardiovascular events using various equations in greeks with metabolic syndrome. Angiology 2010; 61: 49-57.
102. Hu B, Zhou Y, Liu Y, et al. Impact of metabolic syndrome on clinical outcomes after drug-eluting stent implantation in patients with coronary artery disease. Angiology 2011; 62(6): 440-6.
103. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-32.
104. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-14.
105. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-9.
106. Athyros VG, Hatzitolios AI, Karagiannis A, et al; Imperative Col-laborative Group. IMproving the implementation of current guide-lines for the management of major coronary heart disease risk fac-tors by multifactorial intervention. The imperative renal analysis. Arch Med Sci 2011; 7: 984-92
107. Athyros VG, Ganotakis E, Kolovou GD, et al; Assessing the treat-ment effect in metabolic syndrome without perceptible diabetes (Attempt) collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (attempt): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; 9: 647-57.
108. Athyros VG, Karagiannis A, Hatzitolios AI, et al. SAGE-METS collaborative group. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009; 25: 971-80.
109. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Tar-gets 2011; 15: 401-20
110. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptide y levels in patients with type 2 diabetes mellitus: a pilot study. Open Cardiovasc Med J 2011; 5: 136-47
111. Florentin M, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf M, Tselepis A. Effects of rimonabant, as monotherapy and in com-bination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Angiology 2010; 61: 365-71.
112. Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
113. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009; 15: 490-516.
114. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mik-hailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the Fenorli study. Curr Med Res Opin 2005; 21: 1997-2006
115. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of ri-monabant, micronised fenofibrate and their combination on cardi-ometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother 2008; 9: 2741-50.
116. Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007; 47: 642-52.
117. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabi-nod-oriented clinical research after CB1 antagonists. Psychophar-macology (Berl) 2009;205:171-4.
118. Czernichow S, Batty D. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obes Facts 2010; 3: 155-6.
119. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008; 9: 378-87.
120. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interac-tions: a critical review. Drug Saf 2008; 31: 53-65
121. Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Ann Med 2011; 43: 249-58.
122. Bays HE, Gadde KM. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Drugs Today (Barc). 2011; 47: 903-14
123. Bays HE. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther 2011; 9: 265-77
124. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20: 330-42.
125. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAn-nouncements/ucm309993.htm
126. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009; 374: 577-85.
127. Heal DJ, Gosden J, Smith SL. What is the prognosis for new cen-trally-acting antiobesity drugs? Neuropharmacology 2012; 63: 132-46.
128. Available at: http://seekingalpha.com/article/623681-fda-obesity-drug-decisions-on-june-27-and-july-17-will-affect-these-stocks
129. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAn-nouncements/ucm312468.htm
130. Available at: http://www.drugs.com/nda/contrave_110920.html
131. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011; 5: 24-34.
132. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Car-diovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev 2011; 12: 515-24.
133. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mik-hailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11: 122-35.
134. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mik-hailidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010; 8: 12-28.
135. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008; 38: 71-2.
136. Malo E, Ukkola O, Jokela M, et al. Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey. Metab Syndr Relat Disord 2011; 9: 203-210.
137. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update. Horm Metab Res 2012; 44: 6-14.
138. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-27.
139. Shaker O, El-Shehaby A, Zakaria A, et al. Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mel-litus and their relationship to adiposity and fatty liver. Clin Bio-chem 2011; 44: 1457-6.